Evidence map›Paper›PMID 35406455›Full record

ArticleCancers2022

Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer.

Anita Thomas, Kimberly Sue Slade, Roman A Blaheta, Sascha D Markowitsch, Philipp Stenzel, Katrin E Tagscherer, Wilfried Roth, Mario Schindeldecker, Martin Michaelis, Florian Rothweiler and 8 more

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Tumor-infiltrating plasma cells are a prognostic factor in penile squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Anita ThomasDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.
Kimberly Sue SladeDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.
Roman A BlahetaDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.
Sascha D MarkowitschDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.
Philipp StenzelDepartment of Pathology, University Medicine Mainz, 55131 Mainz, Germany.ORCID 0000-0001-8153-5450
Katrin E TagschererDepartment of Pathology, University Medicine Mainz, 55131 Mainz, Germany.ORCID 0000-0002-0657-6399
Wilfried RothDepartment of Pathology, University Medicine Mainz, 55131 Mainz, Germany.
Mario SchindeldeckerDepartment of Pathology, University Medicine Mainz, 55131 Mainz, Germany.ORCID 0000-0003-4843-7992
Martin MichaelisIndustrial Biotechnology Centre, School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK.ORCID 0000-0002-5710-5888
Florian RothweilerInstitute of Medical Virology, Goethe-University, 60596 Frankfurt am Main, Germany.
Jaroslav CinatlInstitute of Medical Virology, Goethe-University, 60596 Frankfurt am Main, Germany.
Robert DotzauerDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.ORCID 0000-0003-1532-4385
Olesya VakhrushevaDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.
Maarten AlbersenDepartment of Urology, University Hospitals Leuven, 28046 Leuven, Belgium.
Axel HaferkampDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.
Eva JuengelDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.ORCID 0000-0002-6321-8707
Jindrich CinatlInstitute of Medical Virology, Goethe-University, 60596 Frankfurt am Main, Germany.
Igor TsaurDepartment of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany.ORCID 0000-0001-5107-3523

Funding

European Urological Scholarship ProgrammeJackstädt StiftungLoercher-Foundation for Medical Research
6 · The paper itself

Abstract

Whereas the lack of biomarkers in penile cancer (PeCa) impedes the development of efficacious treatment protocols, preliminary evidence suggests that c-MET and associated signaling elements may be dysregulated in this disorder. In the following study, we investigated whether c-MET and associated key molecular elements may have prognostic and therapeutic utility in PeCa. Formalin-fixed, paraffin-embedded tumor tissue from therapy-naïve patients with invasive PeCa was used for tissue microarray (TMA) analysis. Immunohistochemical staining was performed to determine the expression of the proteins c-MET, PPARg, β-catenin, snail, survivin, and n-MYC. In total, 94 PeCa patients with available tumor tissue were included. The median age was 64.9 years. High-grade tumors were present in 23.4%, and high-risk HPV was detected in 25.5%. The median follow-up was 32.5 months. High expression of snail was associated with HPV-positive tumors. Expression of β-catenin was inversely associated with grading. In both univariate COX regression analysis and the log-rank test, an increased expression of PPARg and c-MET was predictive of inferior disease-specific survival (DSS). Moreover, in multivariate analysis, a higher expression of c-MET was independently associated with worse DSS. Blocking c-MET with cabozantinib and tivantinib induced a significant decrease in viability in the primary PeCa cell line UKF-PeC3 isolated from the tumor tissue as well as in cisplatin- and osimertinib-resistant sublines. Strikingly, a higher sensitivity to tivantinib could be detected in the latter, pointing to the promising option of utilizing this agent in the second-line treatment setting.

Indexed as

cabozantinibc-METmarkerpenile cancerresistant cell linessquamous cell carcinomatargeted therapytivantinib

Identifiers

PMID35406455
PMCPMC8997038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.